TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1091935

Group type: EXPERIMENTAL
Intervention: Antibiotic mouth rinse (CC10232) used twice a day for one week
Number of subjects: 5
Study: 31617648

Group type: EXPERIMENTAL
Intervention: All for ONE mentoring program (treatment group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 31715434

Group type: EXPERIMENTAL
Intervention: Instantaneous wave‐free ratio‐guided complete revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third‐generation drug‐eluting stents for primary PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting stents for primary PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transradial PCI with the Glidesheath Slender and TR band
Number of subjects: 0
Study: 28655794

Group type: EXPERIMENTAL
Intervention: cediranib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: cabozantinib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: aflibercept
Number of subjects: 5
Study: 26593169

Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 91
Study: 23478616

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization with anopexy (group A, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (group B, n = 20)
Number of subjects: 40
Study: 21113616

Group type: EXPERIMENTAL
Intervention: Response group (n=5) with free Hb(mass) adaptation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Clamp group (n=6) with Hb(mass) negated via phlebotomy
Number of subjects: 11
Study: 19893109

Group type: EXPERIMENTAL
Intervention: High-dose GIK treatment (30% glucose, insulin 2 IU.kg(‐1).l(‐1) and K(+) 80 mmol/l solution; 1 ml/kg/h)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-dose GIK treatment (10% glucose, insulin 32 IU l(‐1) and K(+) 80 mmol/l solution; 1 ml/kg/h)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control treatment (Ringer solution 1 ml/kg/h)
Number of subjects: 49
Study: 17028485

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing and antihyperglycemic agents
Number of subjects: 0
Study: 14999992

Group type: EXPERIMENTAL
Intervention: Drawtex (Vibriant RCD) dressing
Number of subjects: 125

Group type: COMPARATOR
Intervention: Routine practice (standard dressings)
Number of subjects: 125
Study: 11361167

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 64
Study: 9427987

Group type: EXPERIMENTAL
Intervention: One injection of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Number of subjects: 120

Group type: COMPARATOR
Intervention: Two injections of a mixture of balanced salt solution, 2% lidocaine, 0.5% bupivacaine, and hyaluronidase
Number of subjects: 120
Study: 8424029

Group type: EXPERIMENTAL
Intervention: Continue breast-feeding and observe
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Discontinue breast-feeding, substitute formula
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Discontinue breast-feeding, substitute formula and administer phototherapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Continue breast-feeding, administer phototherapy
Number of subjects: 125
Study: 2956067

Group type: EXPERIMENTAL
Intervention: 4 percent chlorhexidine gluconate skin cleanser (Hibiclens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29634989

Group type: EXPERIMENTAL
Intervention: Walnut oil (12% ALA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cream (saturated fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No added fat (control)
Number of subjects: 0
Study: 27225735

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous dexketoprofen prior to surgical incision
Number of subjects: 50

Group type: COMPARATOR
Intervention: 50 mg intravenous dexketoprofen 10 minutes after incision
Number of subjects: 50
Study: 24721980

Group type: EXPERIMENTAL
Intervention: e-Chasqui web-based laboratory information system
Number of subjects: 1671
Study: 23621745

Group type: EXPERIMENTAL
Intervention: One Tiny Reason to Quit (OTRTQ) social marketing campaign promoting quitline calls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One Tiny Reason to Quit (OTRTQ) social marketing campaign
Number of subjects: 0
Study: 19786274

Group type: EXPERIMENTAL
Intervention: Aussie Optimism Program
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual health education lessons (Control)
Number of subjects: 496
Study: 18753802

Group type: EXPERIMENTAL
Intervention: Wrist band group (acupressure on P6 point at both wrists from 30 min before to 24 hr after anesthesia)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wrist band group
Number of subjects: 40
Study: 15721722

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (0.05 microg/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study: 12615023

Group type: EXPERIMENTAL
Intervention: Cavity restoration variables and patient factors
Number of subjects: 27
Study: 10632124

Group type: EXPERIMENTAL
Intervention: Fexofenadine (120, 180, and 240 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Promethazine (10 mg)
Number of subjects: 6
Study: 8861084

Group type: EXPERIMENTAL
Intervention: 1 mg E2 and 0.25 mg NETA (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg E2 and 0.5 mg NETA (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg E2 and 1.0 mg NETA (Group C)
Number of subjects: 60
Study: 1298950

Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 102
Study: 6398313

Group type: EXPERIMENTAL
Intervention: Thymopentin 50 mg via prolonged i.v. injection, 3 times weekly for 3 to 20 weeks.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Different s.c. doses of thymopentin in a crossover fashion for more than two years.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment and medication-free intervals.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thymopentin treatment (overall).
Number of subjects: 8
Study: 29405811

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Red flags (control group)
Number of subjects: 61
Study: 29768139

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canakinumab every 8 weeks after week 16
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26848138

Group type: EXPERIMENTAL
Intervention: Google Glass streaming of vital signs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: User feedback on Google Glass
Number of subjects: 14
Study: 25240700

Group type: EXPERIMENTAL
Intervention: Diet aiming at 5% weight loss over 6 months
Number of subjects: 20
Study: 23190430

Group type: EXPERIMENTAL
Intervention: romiplostim 500μg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: romiplostim 750μg
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 20623233

Group type: EXPERIMENTAL
Intervention: EMLA application for 40 minutes
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: EMLA application for 60 minutes
Number of subjects: 87
Study: 17947390

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Immune globulin
Number of subjects: 1090
Study: 16328288

Group type: EXPERIMENTAL
Intervention: Associative stimulation (1-hour period prior to training)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-associative stimulation (same hand afferents, does not change cortical excitability)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 27
Study: 12730702

Group type: EXPERIMENTAL
Intervention: Adequate intake of folate, B12, and B6 in doses comparable to or above FDA recommendations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Correction of elevated homocyst(e)ine levels with vitamins
Number of subjects: 0
Study: 11201834

Group type: COMPARATOR
Intervention: Standard combined therapy with nonsteroid antiinflammatory drugs, reducers of trophic processes, physiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Standard therapy plus bioresonance treatment (BRT)
Number of subjects: 75
Study: 8645651

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Trace element supplementation
Number of subjects: 1342
Study: 1944470

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf, 5 ml/kg body weight)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 1237
Study: 6342965

Group type: EXPERIMENTAL
Intervention: Osmosin (7 mg indomethacin per hour over a period of approximately 10 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam (20 mg per day for 4 weeks)
Number of subjects: 30
Study: 31910744

Group type: EXPERIMENTAL
Intervention: Idiopathic intracranial hypertension (IIH) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cerebral venous thrombosis (CVT) group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 31264101

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 59
Study: 28389075

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (1% unbuffered sodium hypochlorite and 15% EDTA solution)
Number of subjects: 41
Study: 25888664

Group type: COMPARATOR
Intervention: Continuous Aerobic Exercise (CAE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intermittent Aerobic Exercise (IAE)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-exercising control
Number of subjects: 57
Study: 24425806

Group type: EXPERIMENTAL
Intervention: Reentry programs for adult males
Number of subjects: 1697
Study: 21470359

Group type: EXPERIMENTAL
Intervention: LapSim and ProMIS simulators
Number of subjects: 20

Group type: COMPARATOR
Intervention: LapSim alone or ProMIS alone
Number of subjects: 20
Study: 19296258

Group type: EXPERIMENTAL
Intervention: Cellulose treatment for 2 weeks
Number of subjects: 240
Study: 17726570

Group type: EXPERIMENTAL
Intervention: Insulin plus rosiglitazone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Insulin plus acarbose
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Insulin alone
Number of subjects: 66
Study: 15274106

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone dipropionate (FDP) for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 31
Study: 11387347

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 90
Study: 9234097

Group type: EXPERIMENTAL
Intervention: One plate fixation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Two plate fixation
Number of subjects: 31
Study: 8122302

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO), 125 mg i.m. twice daily five days per week
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-treatment group (placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO)
Number of subjects: 48
Study: 3544839

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (20% protein, 20% fat, 60% carbohydrate, 10% sucrose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat, low-carbohydrate diet (20% protein, 40% fat, 40% carbohydrate, 3% sucrose)
Number of subjects: 0
Study: 29846770

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triple therapy (Ilaprazole 10 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg)
Number of subjects: 32
Study: 27456887

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFNβ‐1a IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25306200

Group type: EXPERIMENTAL
Intervention: IPX066
Number of subjects: 91

Group type: COMPARATOR
Intervention: CL+E
Number of subjects: 91
Study: 22543151

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (hepatoprotective drugs only)
Number of subjects: 63
Study: 20436241

Group type: EXPERIMENTAL
Intervention: Atlanto-occipital joint thrust manipulation
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Soft tissue manual intervention targeted to the suboccipital muscles
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study: 18461096

Group type: EXPERIMENTAL
Intervention: Glucose (1 g x kg body mass(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 11
Study: 17142257

Group type: EXPERIMENTAL
Intervention: Vaccination of care home staff in intervention homes (n=1703)
Number of subjects: 2604

Group type: COMPARATOR
Intervention: No vaccination of care home staff in control homes (n=1703)
Number of subjects: 2604
Study: 12679283

Group type: EXPERIMENTAL
Intervention: 1-year, home- and clinic-based intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 30
Study: 10735538

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg bolus followed by 8 or 4 mg/h infusion)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Cimetidine (800 mg/12 h)
Number of subjects: 629
Study: 9411335

Group type: EXPERIMENTAL
Intervention: 20 mg betaxolol monotherapy
Number of subjects: 21
Study: 1388092

Group type: EXPERIMENTAL
Intervention: etodolac 600 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: piroxicam 20 mg/day
Number of subjects: 116
Study: 2859877

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5-3 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 15-30 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28852985

Group type: EXPERIMENTAL
Intervention: Multistrain Lactobacillus brevis (one vaginal capsule every 12 hours)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Acyclovir (400 mg orally twice daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Multistrain Lactobacillus brevis
Number of subjects: 81

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 81
Study: 28492612

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) therapy (Relieva StratusTM MicroFlow Spacer)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical intranasal corticosteroid therapy (nasal spray)
Number of subjects: 63
Study: 26432775

Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) use from dinner to waking up plus sensor-augmented pump therapy (SAP) during the day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (SAP) only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial pancreas (AP) use
Number of subjects: 0
Study: 24490236

Group type: EXPERIMENTAL
Intervention: Cue-centered treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 65
Study: 21434995

Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly
Number of subjects: 364

Group type: COMPARATOR
Intervention: Sitagliptin to exenatide once-weekly
Number of subjects: 364

Group type: COMPARATOR
Intervention: Pioglitazone to exenatide once-weekly
Number of subjects: 364
Study: 18821092

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol 2 mg + NETA 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 0
Study: 16880021

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior group intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 12499331

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast (69.9 g carbohydrate and 5.2 g protein)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Protein-rich breakfast (15.4 g carbohydrate and 46.8 g protein)
Number of subjects: 9
Study: 10462247

Group type: EXPERIMENTAL
Intervention: S. sonnei-rEPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. flexneri 2a-rEPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study: 8927665

Group type: EXPERIMENTAL
Intervention: Panic disorder patients post-drug trial follow-up
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Baseline disability measures
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Panic attack frequency and phobic avoidance at baseline
Number of subjects: 423
Study: 1842158

Group type: EXPERIMENTAL
Intervention: 2.2% lidocaine hydrocarbonate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.2% lidocaine hydrocarbonate with 1:100,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride with 1:100,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (contralateral canine)
Number of subjects: 30
Study: 6688450

Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxy‐derivatives of vitamin D
Number of subjects: 22
Study: 31351084

Group type: EXPERIMENTAL
Intervention: Calcium silicate + sodium phosphate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular fluoridated toothpaste
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Desensitizing toothpastes (arginine + calcium carbonate, calcium sodium phosphosilicate, strontium acetate, stannous fluoride)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Human saliva
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oligopeptide-104
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stannous chloride + chitosan
Number of subjects: 10
Study: 29949045

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneous (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC
Number of subjects: 0
Study: 27623621

Group type: COMPARATOR
Intervention: Nimodipine alone (30 mg/time, 3 times daily)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Acupuncture alone (30 min/time, 6 times/week)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nimodipine + Acupuncture
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nimodipine alone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 126
Study: 24990088

Group type: EXPERIMENTAL
Intervention: Active drug treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 160
Study: 22633824

Group type: EXPERIMENTAL
Intervention: REGN727 150 mg every 4 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: REGN727 200 mg every 4 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: REGN727 300 mg every 4 weeks
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: REGN727 150 mg every 2 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20673785

Group type: EXPERIMENTAL
Intervention: Pronamel toothpaste applied after demineralization with soft drink
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biorepair Plus toothpaste applied after demineralization with soft drink
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pronamel toothpaste applied to intact enamel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biorepair Plus toothpaste applied to intact enamel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Demineralization with soft drink (control group)
Number of subjects: 50
Study: 17120016

Group type: EXPERIMENTAL
Intervention: 3-day post-loading maintenance diet of 60% carbohydrate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5-day post-loading maintenance diet of 60% carbohydrate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 7-day post-loading maintenance diet of 60% carbohydrate
Number of subjects: 17
Study: 15866433

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional and diffusion-weighted magnetic resonance imaging
Number of subjects: 21
Study: 12370680

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study: 11572048

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Alternative vegetable oils
Number of subjects: 15
Study: 9237054

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 287
Study: 7679269

Group type: EXPERIMENTAL
Intervention: Argon green laser
Number of subjects: 210

Group type: COMPARATOR
Intervention: Krypton red laser
Number of subjects: 210
Study: 3548345

Group type: EXPERIMENTAL
Intervention: Rapid regimen (a mixture of regular and Lente insulins twice daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard regimen (Lente insulin once daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rapid/intravenous regimen (the 'rapid' regimen preceded by overnight intravenous infusion of regular insulin)
Number of subjects: 43
Study: 29087093

Group type: EXPERIMENTAL
Intervention: 0.147% ethyl lauroyl arginate (LAE) mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (CHX) mouthwash
Number of subjects: 40
Study: 27618461

Group type: EXPERIMENTAL
Intervention: Individual peer support from a trained peer specialist
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (other supportive, peer-delivered services excluding individual peer support)
Number of subjects: 113
Study: 24628492

Group type: EXPERIMENTAL
Intervention: Resource ThickenUp Clear (xanthan gum-based thickener)
Number of subjects: 120